CVRx (CVRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Executive summary
The annual meeting is scheduled for June 1, 2026, to be held virtually, with voting on director elections and auditor ratification.
Only stockholders of record as of April 6, 2026, are eligible to vote; 26,430,915 shares are outstanding.
The company remains an emerging growth company until December 31, 2026, and utilizes related reporting exemptions.
Voting matters and shareholder proposals
Stockholders will vote to elect three Class II directors for terms expiring in 2029 and to ratify Grant Thornton LLP as the independent auditor for 2026.
The board recommends voting for all director nominees and for auditor ratification.
Stockholder proposals for the 2027 meeting must be received by December 21, 2026, for inclusion in the proxy statement.
Board of directors and corporate governance
The board will expand to eight members, with three Class II nominees: Michael Dale (new), Kevin Hykes, and Joseph Slattery.
Most directors are independent; Mr. Hykes is not. Mr. Ballinger will become independent board chair after the meeting.
The board is divided into three staggered classes, with annual elections for one class.
Committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
The board holds regular executive sessions and reviews its leadership structure annually.
Latest events from CVRx
- Execution improvements and payer wins position the therapy for broader adoption and growth.CVRX
Canaccord Genuity's 46th Annual Growth Conference - Q2 revenue up 16% year-over-year, but full-year outlook lowered amid sales and payer headwinds.CVRX
Q2 2026 - Barostim therapy gains momentum with expanded access, strong evidence, and accelerating U.S. growth.CVRX
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Barostim's clinical success and new coverage drive heart failure market expansion and access.CVRX
46th Annual William Blair Growth Stock Conference - Directors were elected, auditor ratified, and no stockholder questions were raised.CVRX
AGM 2026 - Q1 2026 revenue rose 20% with strong U.S. growth, margin gains, and market expansion efforts.CVRX
Q1 2026 - Votes are sought for three director nominees and auditor ratification at the 2026 annual meeting.CVRX
Proxy filing - Q4 revenue up 4%, gross margin at 86%, and BENEFIT-HF trial to triple market size.CVRX
Q4 2025 - Refined strategy, reimbursement wins, and expanded market position set the stage for accelerated growth.CVRX
Piper Sandler 36th Annual Healthcare Conference - Q3 revenue up 27% to $13.4M, with Barostim adoption, reimbursement gains, and strong cash reserves.CVRX
Q3 2024